T-cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: Implications for the therapeutic use of CCR5 antagonists

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 3, 2005, Pages 305-309

  Vincent, Thierry ^a,b   Portales, Pierre ^b   Baillat, Vincent ^c   De Boever, Corinne Merle ^c   Le Moing, Vincent ^c   Vidal, Michèle ^c   Ducos, Jacques ^d   Clot, Jacques ^b   Reynes, Jacques ^c   Corbeau, Pierre ^a,b  

^a INSTITUTE OF HUMAN GENETICS   (France)

^b HÔPITAL SAINT ELOI   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d LAPEYRONIE HOSPITAL   (France)

Author keywords

Chemokine; Chemokine receptor; Hepatitis C virus; HIV entry inhibitor; Host factor; Liver

Indexed keywords

AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR5; HLA DR ANTIGEN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL SURFACE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER; LIVER FIBROSIS; LIVER INJURY; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECEPTORS, CCR5; T-LYMPHOCYTES; TRANSAMINASES; VIRAL LOAD;

EID: 20044381655     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Reynes J, Rouzier R, Kanouni T, et al. SCH: safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. Presented at: 9th conference on retroviruses and opportunistic infections, Seattle, WA, 2002.
2. Talal AH, Canchis PW, Jacobson I. The HCV and HIV coinfected patient: what have we learned about pathophysiology? Curr Gastroenterol Rep. 2002;4:15-22.
3. Woitas RP, Ahlenstiel O, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology. 2002;122:1721-1728.
4. Nguyen OT, Carrington M, Beeler JA, et al. Phenotypic expressions of CCR5-Δ32/Δ32 homozygosity. J Acquir Immune Defic Syndr. 1999;22:75-82.
5. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003;38:1468-1476.
6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
7. Rabin RL, Park MK, Liao F, et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol. 1999;162:3840-3850.
8. Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163:6236-6243.
9. Maltby J, Wright S, Bird G, et al. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology. 1996;24:1156-1160.
10. Kusano F, Tanaka Y, Marumo F, et al. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest. 2000;80:415-422.
11. Apolinario A, Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol. 2002;97:2861-2870.
12. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature. 1998;391:908-911.
13. Reynes J, Portales P, Segondy M, et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS. 2001;15: 1627-1634.
14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
15. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
16. Reynes J, Portales P, Segondy M, et al. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis. 2000;181:927-932.
17. Zhang M, Goedert JJ, O'Brien TR. High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology. 2003;124:867-868.
18. Mangia A, Santoro R, D'Agruma L, et al. HCV chronic infection and CCR5-delta32/delta32. Gastroenterology. 2003;124:868-869.
19. Klein RS. Discussion on frequency of the HIV-protective CC chemokine receptor 5-Delta 32/Delta 32 genotype is increased in hepatitis C. Gastroenterology. 2003;124:1558.
20. Poljak M, Seme K, Marin IJ, et al. Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients. Gastroenterology. 2003;124:1558-1560 (author reply: Gastroenterology. 2003;124:60-61).
21. Poljak M, Seme K, Marin IJ, et al. Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients. Gastroenterology. 2003;124:1558-1560 (author reply: Gastroenterology. 2003;124:60-61).
22. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003;124:352-360.